{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:28:21Z","timestamp":1793255301731,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sickle cell disease (SCD) children are frequent travellers to countries where yellow fever (YF) is endemic, but there are no data regarding the safety and immunogenicity of the vaccine in such children treated with hydroxyurea (HU). The main objective of this study was to compare the tolerance and immune response to YF vaccination in SCD children treated or not with HU.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>SCD children &amp;lt;\u200918\u00a0years attending the international travel clinics of three large paediatric centres and requiring a first YF vaccination were included in a prospective study. Adverse events were collected 2\u00a0weeks after vaccination. YF vaccine antibody titres were measured ~6\u00a0months after vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 52 SCD children vaccinated against YF, 17 (33%) were treated with HU. Only mild adverse events, mainly fever and local reaction, were observed in the HU group with a similar frequency in the non-HU group (57 and 35%, respectively, P\u2009=\u00a00.30). YF antibody titres were measured in 15\/17 patients in the HU group and 23\/35 patients in the non-HU group after a median of 6.0\u00a0months (3.5\u20138.5) following vaccination. The geometric mean of YF antibody titre was similar in both groups. A protective antibody level was observed in 85% of the children in the HU group vs 100% in the non-HU group (P\u2009=\u20090.14), suggesting a lower effectiveness of the vaccine in patients on HU similarly to what has been described in patients on immune suppressive therapy for other vaccines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>YF vaccination seems to be safe and efficient in SCD children treated with HU. Considering the potential risk of severe complications in cases of YF while travelling in Africa for those patients, the benefit-to-risk ratio argues for YF vaccination in all SCD children. Control of a protective antibody titre may also be useful to ascertain an adequate response in those treated with HU.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taab013","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T13:28:41Z","timestamp":1612531721000},"source":"Crossref","is-referenced-by-count":6,"title":["Tolerance and humoral immune response to the yellow fever vaccine in sickle cell disease children treated with hydroxyurea: a multicentre prospective study"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-7199","authenticated-orcid":false,"given":"Berengere","family":"Koehl","sequence":"first","affiliation":[{"name":"Department of Haematology, Reference Centre of Sickle Cell Disease, H\u00f4pital Robert Debr\u00e9, APHP, 48 Bd S\u00e9rurier, Paris 75019, France"},{"name":"Universit\u00e9 de Paris, 48 Bld Serurier, 75019, Paris, France"},{"name":"INSERM UMRS 1134, BIGR, 6 rue Alexandre Cabanel, 75015, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Aupiais","sequence":"additional","affiliation":[{"name":"INSERM UMRS 1123, ECEVE, 10 avenue de Verdun 75010, Paris, France"},{"name":"Department of Paediatrics Emergency, Jean Verdier Hospital, APHP, Bondy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Schinckel","sequence":"additional","affiliation":[{"name":"Department of General Paediatrics and Infectious Diseases, Robert Debr\u00e9 Hospital, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Mornand","sequence":"additional","affiliation":[{"name":"Department of General Paediatrics, Centre for Sickle Cell Disease, Trousseau Hospital, APHP, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Odi\u00e8vre","sequence":"additional","affiliation":[{"name":"INSERM UMRS 1134, BIGR, 6 rue Alexandre Cabanel, 75015, Paris, France"},{"name":"Department of General Paediatrics, Centre for Sickle Cell Disease, Trousseau Hospital, APHP, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assa","family":"Niakate","sequence":"additional","affiliation":[{"name":"Department of General Paediatrics, Centre for Sickle Cell Disease, Trousseau Hospital, APHP, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Brousse","sequence":"additional","affiliation":[{"name":"INSERM UMRS 1134, BIGR, 6 rue Alexandre Cabanel, 75015, Paris, France"},{"name":"Department of General Paediatrics, Necker-Enfants malades hospital, APHP, 149 rue de Sevres, 75015, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislaine","family":"Ithier","sequence":"additional","affiliation":[{"name":"Department of Haematology, Reference Centre of Sickle Cell Disease, H\u00f4pital Robert Debr\u00e9, APHP, 48 Bd S\u00e9rurier, Paris 75019, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Missud","sequence":"additional","affiliation":[{"name":"Department of Haematology, Reference Centre of Sickle Cell Disease, H\u00f4pital Robert Debr\u00e9, APHP, 48 Bd S\u00e9rurier, Paris 75019, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Holvoet","sequence":"additional","affiliation":[{"name":"Department of Haematology, Reference Centre of Sickle Cell Disease, H\u00f4pital Robert Debr\u00e9, APHP, 48 Bd S\u00e9rurier, Paris 75019, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Benkerrou","sequence":"additional","affiliation":[{"name":"Department of Haematology, Reference Centre of Sickle Cell Disease, H\u00f4pital Robert Debr\u00e9, APHP, 48 Bd S\u00e9rurier, Paris 75019, France"},{"name":"INSERM UMRS 1123, ECEVE, 10 avenue de Verdun 75010, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Sorge","sequence":"additional","affiliation":[{"name":"Department of Haematology, Reference Centre of Sickle Cell Disease, H\u00f4pital Robert Debr\u00e9, APHP, 48 Bd S\u00e9rurier, Paris 75019, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Faye","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, 48 Bld Serurier, 75019, Paris, France"},{"name":"INSERM UMRS 1123, ECEVE, 10 avenue de Verdun 75010, Paris, France"},{"name":"Department of General Paediatrics and Infectious Diseases, Robert Debr\u00e9 Hospital, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,6]]},"reference":[{"key":"2021122014314526000_ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taz040","article-title":"Severe yellow fever in Brazil: clinical characteristics and management","volume":"26","author":"Ho","year":"2019","journal-title":"J Travel Med"},{"key":"2021122014314526000_ref2","doi-asserted-by":"publisher","first-page":"e1001638","DOI":"10.1371\/journal.pmed.1001638","article-title":"Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data","volume":"11","author":"Garske","year":"2014","journal-title":"PLoS Med"},{"key":"2021122014314526000_ref3","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay097","article-title":"Pandemic yellow fever: a potential threat to global health via travelers","volume":"25","author":"Gubler","year":"2018","journal-title":"J Travel Med"},{"key":"2021122014314526000_ref4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet"},{"key":"2021122014314526000_ref5","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.vaccine.2013.01.054","article-title":"Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010","volume":"31","author":"Breugelmans","year":"2013","journal-title":"Vaccine"},{"key":"2021122014314526000_ref6","volume-title":"Detection and Investigation of Serious Adverse Events Following Yellow Fever Vaccination","author":"WHO","year":"2008"},{"key":"2021122014314526000_ref7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122014314526000_ref8","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1182\/blood.V88.6.1960.bloodjournal8861960","article-title":"Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial","volume":"88","author":"Ferster","year":"1996","journal-title":"Blood"},{"key":"2021122014314526000_ref9","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1542\/peds.2008-0441","article-title":"Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children","volume":"122","author":"Strouse","year":"2008","journal-title":"Pediatrics"},{"key":"2021122014314526000_ref10","first-page":"1069","article-title":"Management of sickle cell disease: recommendations from the 2014 expert panel report","volume":"92","author":"Yawn","year":"2015","journal-title":"Am Fam Physician"},{"key":"2021122014314526000_ref11","author":"HYDREA (hydroxyurea) product monograph:"},{"key":"2021122014314526000_ref12"},{"key":"2021122014314526000_ref13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tmaid.2014.12.007","article-title":"Travel risk assessment, advice and vaccinations in immunocompromised travellers (HIV, solid organ transplant and haematopoeitic stem cell transplant recipients): a review","volume":"13","author":"Aung","year":"2015","journal-title":"Travel Med Infect Dis"},{"key":"2021122014314526000_ref14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"2021122014314526000_ref15","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1097\/QAD.0000000000001963","article-title":"Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients","volume":"32","author":"Colin de Verdiere","year":"2018","journal-title":"AIDS Lond Engl"},{"key":"2021122014314526000_ref16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ebiom.2015.07.002","article-title":"A retrospective analysis of the significance of haemoglobin SS and SC in disease outcome in patients with sickle cell disease and dengue fever","volume":"2","author":"Rankine-Mullings","year":"2015","journal-title":"EBioMedicine"},{"key":"2021122014314526000_ref17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3201\/eid2205.151934","article-title":"Fatal sickle cell disease and Zika virus infection in girl from Colombia","volume":"22","author":"Arzuza-Ortega","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2021122014314526000_ref18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jiph.2019.07.015","article-title":"Dengue in hospitalized children with sickle cell disease: a retrospective cohort study in the French departments of America","volume":"13","author":"Elenga","year":"2020","journal-title":"J Infect Public Health"},{"key":"2021122014314526000_ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay136","article-title":"Risk of severe dengue is higher in patients with sickle cell disease: a scoping review","volume":"26","author":"Wilder-Smith","year":"2019","journal-title":"J Travel Med"},{"key":"2021122014314526000_ref20","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1016\/j.vaccine.2005.12.055","article-title":"Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine","volume":"24","author":"Hepburn","year":"2006","journal-title":"Vaccine"},{"key":"2021122014314526000_ref21","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taz015","article-title":"Yellow fever vaccination for immunocompromised travellers: unjustified vaccination hesitancy?","volume":"26","author":"Jong","year":"2019","journal-title":"J Travel Med"},{"key":"2021122014314526000_ref22","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taz034","article-title":"Travel vaccination recommendations and infection risk in HIV-positive travellers","volume":"26","author":"Chang","year":"2019","journal-title":"J Travel Med"},{"key":"2021122014314526000_ref23","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay018","article-title":"Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations","volume":"25","author":"Hall","year":"2018","journal-title":"J Travel Med"},{"key":"2021122014314526000_ref24","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2004-12-4973","article-title":"Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study","volume":"106","author":"Hankins","year":"2005","journal-title":"Blood"},{"key":"2021122014314526000_ref25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1542\/peds.2014-0571","article-title":"Immunologic effects of hydroxyurea in sickle cell anemia","volume":"134","author":"Lederman","year":"2014","journal-title":"Pediatrics"},{"key":"2021122014314526000_ref26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2021122014314526000_ref27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru","volume":"72","author":"Belmusto-Worn","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"2021122014314526000_ref28","first-page":"11","article-title":"An overview of the clinical experience with hydroxyurea","volume":"19","author":"Donehower","year":"1992","journal-title":"Semin Oncol"},{"key":"2021122014314526000_ref29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/pr.2013.85","article-title":"Transgenic sickle cell disease mice have high mortality and dysregulated immune responses after vaccination","volume":"74","author":"Szczepanek","year":"2013","journal-title":"Pediatr Res"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taab013\/36337265\/taab013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/28\/3\/taab013\/41826066\/taab013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/28\/3\/taab013\/41826066\/taab013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T14:40:28Z","timestamp":1640011228000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taab013\/6129658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,6]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,2,6]]},"published-print":{"date-parts":[[2021,4,14]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taab013","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2021,2,6]]},"article-number":"taab013"}}